These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17123566)

  • 1. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
    Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
    Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.
    Pashov A; MacLeod S; Saha R; Perry M; VanCott TC; Kieber-Emmons T
    Glycobiology; 2005 Oct; 15(10):994-1001. PubMed ID: 15917430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.
    Lee HK; Scanlan CN; Huang CY; Chang AY; Calarese DA; Dwek RA; Rudd PM; Burton DR; Wilson IA; Wong CH
    Angew Chem Int Ed Engl; 2004 Feb; 43(8):1000-3. PubMed ID: 14966891
    [No Abstract]   [Full Text] [Related]  

  • 6. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design.
    Wang LX; Ni J; Singh S; Li H
    Chem Biol; 2004 Jan; 11(1):127-34. PubMed ID: 15113002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
    Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
    AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
    Sanders RW; Venturi M; Schiffner L; Kalyanaraman R; Katinger H; Lloyd KO; Kwong PD; Moore JP
    J Virol; 2002 Jul; 76(14):7293-305. PubMed ID: 12072528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12.
    Marradi M; Di Gianvincenzo P; Enríquez-Navas PM; Martínez-Ávila OM; Chiodo F; Yuste E; Angulo J; Penadés S
    J Mol Biol; 2011 Jul; 410(5):798-810. PubMed ID: 21440555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
    Pantophlet R; Wilson IA; Burton DR
    Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
    Scanlan CN; Pantophlet R; Wormald MR; Ollmann Saphire E; Stanfield R; Wilson IA; Katinger H; Dwek RA; Rudd PM; Burton DR
    J Virol; 2002 Jul; 76(14):7306-21. PubMed ID: 12072529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    Trkola A; Purtscher M; Muster T; Ballaun C; Buchacher A; Sullivan N; Srinivasan K; Sodroski J; Moore JP; Katinger H
    J Virol; 1996 Feb; 70(2):1100-8. PubMed ID: 8551569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
    Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
    Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
    Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.
    Balzarini J; Van Laethem K; Hatse S; Froeyen M; Van Damme E; Bolmstedt A; Peumans W; De Clercq E; Schols D
    Mol Pharmacol; 2005 May; 67(5):1556-65. PubMed ID: 15718224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
    Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region.
    Masuda T; Matsushita S; Kuroda MJ; Kannagi M; Takatsuki K; Harada S
    J Immunol; 1990 Nov; 145(10):3240-6. PubMed ID: 1700002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
    Gray ES; Moore PL; Pantophlet RA; Morris L
    J Virol; 2007 Oct; 81(19):10769-76. PubMed ID: 17634239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.